Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Renowned Geneticist Philip Beales Launches Axovia Therapeutics to Develop Transformative Medicines for Ciliopathies
Axovia is a majority-owned subsidiary of Jaguar Gene Therapy, which is backed by Deerfield Management
LONDON, Feb. 25, 2021an innovative gene therapy company developing disease-transformative medicines for ciliopathies, led by renowned researcher Professor Philip Beales, launched today after being in stealth mode for the past year. Axovia is a majority-owned subsidiary of Jaguar Gene Therapy, which is backed by Deerfield Management, and is also partially funded by
UCL Technology Fund. Axovia is receiving initial operational support from Jaguar Gene Therapy, including critical manufacturing guidance intended to expedite Axovia s development timelines and enable it to bring its much-needed discoveries to patients.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva Reports FY 2020 Results and Major Corporate Achievements
VALNEVAFebruary 25, 2021 GMT
Excellent progress on clinical programs
Unprecedented partnering deal signed with Pfizer for Lyme disease vaccine candidate VLA15, including $130 million upfront payment as part of over $300 million for upfront and milestone payments
Positive initial Phase 2 results
Acceleration of pediatric development announced
Acceleration of chikungunya vaccine candidate VLA1553 into Phase 3
Only Phase 3 chikungunya vaccine program to date worldwide
Potentially eligible for Priority Review Voucher (PRV)1 - for first company to receive Biologics License Application (BLA) approval
Investegate |Axovia Therapeutics Announcements | Axovia Therapeutics: Renowned Geneticist Philip Beales Launches Axovia Therapeutics to Develop Transformative Medicines for Ciliopathies investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Published: Feb 24, 2021
Feb. 24, 2021 11:00 UTC
Deal led by Rock Springs Capital and joined by Bain Capital Life Sciences, Deerfield Management, RA Capital Management and other investors
Proceeds will advance XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4) into the clinic
Two investigational new drug (IND) applications planned in 2021
Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the successful closing of a $95 million Series C financing. Proceeds from the financing will be used to advance Xilio’s lead therapeutic candidates, XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4 mAb), into clinical trials. Investigational new drug (IND) applications for XTX202 and XTX101 are expected to be filed with the U.S. Food and Drug Administration (FDA) in 2021.